Since our in vitro result indicated the relevance of PMN–Plts aggregates for netosis potentiation and endothelial damage in Stx2+LPS treatment, and given that HUS patients also show increased circulating aggregates (Ståhl et al., 2009), we first determine if mixed PMN–Plts aggregates were increased in LPS+Stx2-treated animals. The gene discussed is STX2; the disease is hemolytic-uremic syndrome.